KR910019630A - 프라바스타틴 및 제약상 허용되는 담체로 이루어진 혈관형성수술후의 재협착 발생 방지용 제약 조성물 - Google Patents

프라바스타틴 및 제약상 허용되는 담체로 이루어진 혈관형성수술후의 재협착 발생 방지용 제약 조성물 Download PDF

Info

Publication number
KR910019630A
KR910019630A KR1019910008932A KR910008932A KR910019630A KR 910019630 A KR910019630 A KR 910019630A KR 1019910008932 A KR1019910008932 A KR 1019910008932A KR 910008932 A KR910008932 A KR 910008932A KR 910019630 A KR910019630 A KR 910019630A
Authority
KR
South Korea
Prior art keywords
composition
ace inhibitor
derivative
pravastatin
angiogenesis
Prior art date
Application number
KR1019910008932A
Other languages
English (en)
Inventor
이. 맥거번 마크
에이. 온데티 미구엘
와이. 팬 헨리
Original Assignee
니콜라스 피. 말라테스티닉
이이. 아르.스퀴브 앤드 산즈, 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니콜라스 피. 말라테스티닉, 이이. 아르.스퀴브 앤드 산즈, 인크 filed Critical 니콜라스 피. 말라테스티닉
Publication of KR910019630A publication Critical patent/KR910019630A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

내용 없음

Description

프라바스타틴 및 제약상 허용되는 담체로 이루어진 혈관형성수술후의 재협착 발생 방지용 제약 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (16)

  1. 활성 성분인 프라바스타틴과 제약상 허용되는 담체 또는 부형제로 이루어짐을 특징으로 하는, 혈관형성수술후 재협착의 위험을 방지 또는 경감시키기 위한 제약 조성물.
  2. 제1항에 있어서, 상기 프러바스타틴이 1일 약 1내기2000mg의 양으로 1회 내지 4회의 단일 또는 분할 투여량을 제공할 수 있는 양으로 존재함을 특징으로 하는 조성물.
  3. 제1항에 있어서, 상기 프러바스타틴이 1일 약 4내지 200mg의 양으로 1회 내지 4회의 단일 또는 분할 투여량을 제공할 수 있는 양으로 존재함을 특징으로 하는 조성물.
  4. 제1항에 있어서, 혈관형성수술 전에 투여됨을 특징으로 하는 조성물.
  5. 제1항에 있어서, 혈관형성수술 중에 투여됨을 특징으로 하는 조성물.
  6. 제1항에 있어서, 혈관형성수술 후에 투여됨을 특징으로 하는 조성물.
  7. 활성 성분인 프라바스타틴과 ACE억제제가 혼합되어 이루어짐을 특징으로 하는, 혈관형성수술 후 재협착의 위험을 방지 또는 경감시키기 위한 제약 조성물.
  8. 제7항에 있어서, 상기 ACE억제제가 치환 프롤린 유도체임을 특징으로 하는 조성물.
  9. 제7항에 있어서, 상기 ACE억제제가 메르캅토기를 함유하는 치환 프롤린 유도체임을 특징으로 하는 조성물.
  10. 제7항에 있어서, 상기 ACE억제제가 캡토프릴, 조페노프릴, 엔알라프릴, 세라나프릴, 포시노프릴, 리시노프릴 또는 펜티아프릴 임을 특징으로 하는 조성물.
  11. 제7항에 있어서, 상기 ACE억제제가 포스포네이트 치환 아미노산 또는 이미노산 또는 그의 염, 프롤린 유도체, 치환 프롤린 유도체, 치환 프롤린의 메프캅토아실 유도체, 카르복시알킬 디펩티드 유도체, 포스피닐알카노일 프롤린 유도체, 또는 포스폰아미데이트 유도체임을 특징으로 하는 조성물.
  12. 제11항에 잇어서, 상기 ACE억제제가 카르복시알킬 디펩티드 유도체임을 특징으로 하는 조성물.
  13. 제7항에 잇어서, 상기 ACE억제제가 포스피닐알카노일 프롤린 유도체, 포스폰아미데이트 유도체, 또는 포스포네이트 치환 아미노산 또는 이미노산 또는 그의 염임을 특징으로 하는 조성물.
  14. 제7항에 있어서, 상기 프라바스타틴이 상기 ACE억제제에 대해 약0.001:1내지 약1000:1범위의 중량비로 존재함을 특징으로 하는 조성물.
  15. 제7항에 있어서, 상기 ACE억제제가 1일 약0.1내지500mg의 양으로 1회내지 4회의 단일 또는 분할 투여량을 제공할 수 있는 양으로 존재함을 특징으로 하는 조성물.
  16. 제7항에 있어서, 상기 ACE억제제가 캡토프릴, 포시노프릴, 또는 세라나프릴임을 특징으로 하는 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019910008932A 1990-05-31 1991-05-30 프라바스타틴 및 제약상 허용되는 담체로 이루어진 혈관형성수술후의 재협착 발생 방지용 제약 조성물 KR910019630A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/532,009 US5140012A (en) 1990-05-31 1990-05-31 Method for preventing onset of restenosis after angioplasty employing pravastatin
US532,009 1990-05-31

Publications (1)

Publication Number Publication Date
KR910019630A true KR910019630A (ko) 1991-12-19

Family

ID=24120034

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910008932A KR910019630A (ko) 1990-05-31 1991-05-30 프라바스타틴 및 제약상 허용되는 담체로 이루어진 혈관형성수술후의 재협착 발생 방지용 제약 조성물

Country Status (10)

Country Link
US (1) US5140012A (ko)
EP (1) EP0459453A3 (ko)
JP (1) JPH04235915A (ko)
KR (1) KR910019630A (ko)
AU (1) AU646042B2 (ko)
CA (1) CA2041951A1 (ko)
HU (1) HUT58516A (ko)
IE (1) IE911780A1 (ko)
PT (1) PT97806A (ko)
ZA (1) ZA913725B (ko)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2042159A1 (en) * 1990-05-31 1991-12-01 Miguel A. Ondetti Method for preventing onset of restenosis after angioplasty employing an ace inhibitor
CA2042526A1 (en) * 1990-06-11 1991-12-12 Adeoye Y. Olukotun Method for preventing a second heart attack employing an hmg coa reductase inhibitor
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
EP1447098A3 (en) * 1993-01-28 2005-06-29 Boston Scientific Limited Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5681278A (en) * 1994-06-23 1997-10-28 Cormedics Corp. Coronary vasculature treatment method
US5602110A (en) * 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
CA2215731A1 (en) * 1995-03-20 1996-09-26 Allergan Use of retinoids for the manufacture of a medicament for the treatment of restenosis
CA2223595C (en) 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5900433A (en) * 1995-06-23 1999-05-04 Cormedics Corp. Vascular treatment method and apparatus
EP0946178A4 (en) * 1996-09-18 2003-05-07 Merck & Co Inc COMBINATION THERAPY TO REDUCE THE RISKS OF HEART CIRCULAR DISEASES
US6235706B1 (en) 1996-09-18 2001-05-22 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US5902299A (en) * 1997-07-29 1999-05-11 Jayaraman; Swaminathan Cryotherapy method for reducing tissue injury after balloon angioplasty or stent implantation
US6180660B1 (en) 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
US6034110A (en) * 1998-01-12 2000-03-07 Allergan Sales, Inc. Method for preventing onset of restenosis after angioplasty employing an RXR-specific retinoid and a PPARγ ligand
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
AU2007200367B2 (en) * 1999-02-06 2010-04-08 Astrazeneca Ab Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
DE60022525T2 (de) * 1999-08-30 2006-06-14 Sanofi Aventis Deutschland Ramipril zur vorbeugung von kardiovaskulären vorfällen
MXPA02005283A (es) * 1999-11-30 2003-10-06 Biogal Gyogyszergyar Proceso para recuperar compuestos estatina de un caldo de fermentacion.
IL150187A0 (en) * 1999-12-14 2002-12-01 Biogal Pharmaceutical Co Ltd Novel forms of pravastatin sodium
US20020183383A1 (en) * 2001-02-27 2002-12-05 Rene Belder Pharmaceutical compositions
US6692772B2 (en) * 2001-07-18 2004-02-17 Cedars-Sinai Medical Center Prevention of in-stent thrombosis and complications after arterial angioplasty with stent placement using magnesium
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6576256B2 (en) 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20030077310A1 (en) 2001-10-22 2003-04-24 Chandrashekhar Pathak Stent coatings containing HMG-CoA reductase inhibitors
US7107198B2 (en) * 2001-11-02 2006-09-12 Sun Microsystems, Inc. Automatic generation of reduced-size circuit models including inductive interaction
DE602004017461D1 (de) * 2003-11-24 2008-12-11 Teva Gyogyszergyar Zartkoeruen Verfahren zur reinigung von pravastatin
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
TW200640854A (en) * 2005-02-09 2006-12-01 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Methods of making pravastatin sodium
US20060205727A1 (en) * 2005-03-11 2006-09-14 Wayne Kaesemeyer Combination therapy for endothelial dysfunction, angina and diabetes
EP2405747A4 (en) * 2009-03-13 2013-01-16 Nucitec Sa De Cv COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
DE3536687A1 (de) * 1985-10-15 1987-04-16 Hoechst Ag Verfahren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit
ZA896851B (en) * 1988-09-14 1990-06-27 Hoffmann La Roche Use of ace-inhibitors

Also Published As

Publication number Publication date
AU7727591A (en) 1991-12-05
EP0459453A3 (en) 1993-02-24
JPH04235915A (ja) 1992-08-25
AU646042B2 (en) 1994-02-03
HUT58516A (en) 1992-03-30
PT97806A (pt) 1992-02-28
CA2041951A1 (en) 1991-12-01
EP0459453A2 (en) 1991-12-04
US5140012A (en) 1992-08-18
HU911815D0 (en) 1991-12-30
ZA913725B (en) 1992-02-26
IE911780A1 (en) 1991-12-04

Similar Documents

Publication Publication Date Title
KR910019630A (ko) 프라바스타틴 및 제약상 허용되는 담체로 이루어진 혈관형성수술후의 재협착 발생 방지용 제약 조성물
GEP20012549B (en) Pharmaceutical Composition Containing Sumatriptan
GEP20032925B (en) Benzothiepines Having Activity As Inhibitors of Ileal Bile Acid Transport and Taurocholate Uptake
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
ATE130758T1 (de) Arzneimittel zur intranasalen verabreichung, die ketorolac r enthalten.
PT101061A (pt) Composicoes farmaceuticas contendo anagolos da camptotecina e um composto de coordenacao de platina e seu uso na inibicao do crescimento de celulas tumorais
IL104090A (en) Phosphonosuccinic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing these compounds
RU2008103617A (ru) Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
ATE158504T1 (de) Brausemischungen enthaltend ibuprofen und verfahren
PT1095654E (pt) Utilizacao de raloxifeno e dos seus analogos para a manufactura de um medicamento para a inibicao da oxidacao de ldl e aterosclerose
ATE220321T1 (de) Feste flupirtin enthaltende orale darreichungsformen mit kontrollierter wirkstoffabgabe
CA2003289A1 (en) Use of trifluoromethylphenyl-tetrahydropyridines for the preparation of pharmaceutical compositions useful for the treatment of anxiety and anxio-depressive disorders
KR970061249A (ko) 골다공증을 치료 또는 방지하기 위한 조성물
KR960034200A (ko) 항편두통성 인돌릴알킬-피리딘일 및 피리미딘일피페라진의 1,2,5-티아디아졸 유도체
HK1018783A1 (en) BENZO[C]QUINOLIZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5 α-REDUCTASES INHIBITORS
UA40636C2 (uk) Фармацевтична композиція для одержання стабільного порошку, яка містить як активний компонент асоціацію ацетилсаліцилової кислоти та метоклопраміду, фармацевтичний препарат у формі порошку та спосіб одержання цього препарату
HUT61009A (en) Process for producing 1,4-dihydropyridine derivatives and pharmaceutical compositions comprising same as active ingredient
GB2258397A (en) Pharmaceutical compositions containing amethocaine
ES2065855A1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
YU81101A (sh) Polimorfni oblici kristalnog citrata azabiciklo (2,2,2) oktan-3-amina i njihovih farmaceutskih kompozicija
ES8405614A1 (es) Procedimiento de preparar farmacos con liberacion programada de materia activa.
US5478815A (en) Liver protectant tocophery-ascorbyl-phosphate
RU2006119451A (ru) Cci-79 для лечения лимфомы из мантийных клеток
IT1293835B1 (it) Composizioni farmaceutiche orali in forma solida a cessione modulata contenenti nicorandil e procedimento per la loro preparazione

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application